局部瘤内递送免疫调节剂治疗口腔癌和口腔潜在恶性疾病。
Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.
机构信息
Katz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry, 7500 Cambridge St, SOD-6510, Houston, TX 77054, USA.
Katz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry, 7500 Cambridge St, SOD-6510, Houston, TX 77054, USA; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Pickens-1550, Houston, TX 77030, USA.
出版信息
Oral Oncol. 2024 Nov;158:106986. doi: 10.1016/j.oraloncology.2024.106986. Epub 2024 Aug 12.
Immunotherapy has developed into an important modality of modern cancer treatment. Unfortunately, checkpoint inhibitor immunotherapies are currently delivered systemically and require frequent administration, which can result in toxicity and severe, sometimes fatal, adverse events. Localized delivery of immunomodulators for oral cancer and oral potentially malignant disorders offers the promise of maximum therapeutic potential and reduced systemic adverse effects. This review will discuss the limitations of current standard-of-care systemic therapies and highlight research advances in localized, intratumoral delivery platforms for immunotherapy for oral cancer and oral potentially malignant disorders.
免疫疗法已经发展成为现代癌症治疗的一种重要手段。不幸的是，目前的检查点抑制剂免疫疗法是全身性给药的，需要频繁给药，这可能导致毒性和严重的、有时甚至是致命的不良反应。口腔癌和口腔潜在恶性疾病的免疫调节剂的局部给药为最大的治疗潜力和减少全身不良反应提供了可能。本文将讨论当前标准治疗的全身性治疗的局限性，并强调口腔癌和口腔潜在恶性疾病的局部、肿瘤内免疫治疗的靶向递药平台的研究进展。
Zotero 插件